- Home
- PHAR vs RGR Comparison
PHAR vs RGR Comparison
Compare PHAR & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- RGR
- Stock Information
- Founded
- PHAR 1988
- RGR 1949
- Country
- PHAR Netherlands
- RGR United States
- Employees
- PHAR N/A
- RGR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- PHAR Health Care
- RGR Industrials
- Exchange
- PHAR Nasdaq
- RGR Nasdaq
- Market Cap
- PHAR 731.1M
- RGR 616.8M
- IPO Year
- PHAR N/A
- RGR N/A
- Fundamental
- Price
- PHAR $9.88
- RGR $36.12
- Analyst Decision
- PHAR Strong Buy
- RGR
- Analyst Count
- PHAR 3
- RGR 0
- Target Price
- PHAR $30.00
- RGR N/A
- AVG Volume (30 Days)
- PHAR 4.3K
- RGR 190.3K
- Earning Date
- PHAR 07-31-2025
- RGR 07-30-2025
- Dividend Yield
- PHAR N/A
- RGR 1.94%
- EPS Growth
- PHAR N/A
- RGR N/A
- EPS
- PHAR N/A
- RGR 1.83
- Revenue
- PHAR $320,708,000.00
- RGR $534,561,000.00
- Revenue This Year
- PHAR $13.31
- RGR N/A
- Revenue Next Year
- PHAR $7.68
- RGR $1.89
- P/E Ratio
- PHAR N/A
- RGR $19.70
- Revenue Growth
- PHAR 24.13
- RGR 0.65
- 52 Week Low
- PHAR $6.65
- RGR $32.74
- 52 Week High
- PHAR $12.61
- RGR $46.40
- Technical
- Relative Strength Index (RSI)
- PHAR 40.64
- RGR 46.30
- Support Level
- PHAR $10.46
- RGR $35.53
- Resistance Level
- PHAR $11.49
- RGR $36.82
- Average True Range (ATR)
- PHAR 0.31
- RGR 0.76
- MACD
- PHAR -0.16
- RGR -0.03
- Stochastic Oscillator
- PHAR 0.00
- RGR 27.20
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.